Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald

Belite Bio (NASDAQ:BLTE) had its price objective increased by Cantor Fitzgerald from $200.00 to $266.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities analysts have also issued reports on BLTE. Bank of America began coverage on Belite Bio in a research report on Monday, January 26th. They issued a “buy” rating and a $195.00 target price on the stock. Morgan Stanley began coverage on shares of Belite Bio in a report on Tuesday, January 6th. They issued an “overweight” rating and a $191.00 price target on the stock. Mizuho set a $223.00 price objective on shares of Belite Bio in a research note on Thursday, February 19th. Benchmark reissued a “buy” rating on shares of Belite Bio in a research report on Wednesday, December 3rd. Finally, Wall Street Zen cut shares of Belite Bio from a “hold” rating to a “sell” rating in a research report on Sunday, January 4th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $202.33.

Belite Bio Price Performance

Belite Bio stock opened at $167.88 on Tuesday. The firm’s fifty day moving average price is $168.93 and its 200 day moving average price is $123.30. The company has a market capitalization of $6.30 billion, a price-to-earnings ratio of -72.99 and a beta of -1.46. Belite Bio has a 12-month low of $49.00 and a 12-month high of $200.00.

Belite Bio (NASDAQ:BLTE) last announced its earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.18. Analysts forecast that Belite Bio will post -1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Belite Bio

Several hedge funds and other institutional investors have recently made changes to their positions in BLTE. Darwin Global Management Ltd. acquired a new stake in Belite Bio in the 4th quarter valued at approximately $486,915,000. RA Capital Management L.P. acquired a new position in Belite Bio during the 3rd quarter worth $64,750,000. Millennium Management LLC grew its stake in shares of Belite Bio by 2,594.6% in the fourth quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock worth $89,399,000 after purchasing an additional 538,141 shares in the last quarter. RTW Investments LP grew its stake in shares of Belite Bio by 128.9% in the fourth quarter. RTW Investments LP now owns 715,332 shares of the company’s stock worth $114,425,000 after purchasing an additional 402,832 shares in the last quarter. Finally, Perceptive Advisors LLC increased its holdings in shares of Belite Bio by 732.0% during the fourth quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock valued at $66,262,000 after purchasing an additional 364,451 shares during the period. 0.53% of the stock is currently owned by institutional investors and hedge funds.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Multiple brokerages raised targets and ratings — Cantor Fitzgerald to $266 (overweight), Morgan Stanley to $201 (overweight), and HC Wainwright to $200 (buy), implying high upside from current levels and reflecting bullish analyst conviction. Analyst Price Target Raises
• Positive Sentiment: Belite reported a Q4 beat: EPS of ($0.38) vs. consensus ($0.56), which reduces near-term execution risk and supports valuation upgrades. Earnings Results & Call
• Positive Sentiment: Company update targets a Q2 2026 NDA submission for its Stargardt program and plans $200M–$250M commercialization spend; management also reports rising cash reserves — this is a material development for future revenue potential and commercialization planning. NDA Timeline & Commercialization Plan
• Neutral Sentiment: Belite will participate in investor conferences (Leerink Global Healthcare), and transcripts/slides from the earnings call are available — helpful for due diligence but not immediate stock-moving by themselves. Conference Participation
• Neutral Sentiment: Multiple earnings-call transcripts and the company’s preliminary Q4/full-year press release and slide deck were published — useful context for analysts and investors. Press Release & Slides
• Neutral Sentiment: Short-interest entries published appear inconsistent (reports show “0 shares” and NaN changes, days-to-cover 0.0) — the data looks erroneous, creating unclear signal regarding bearish positioning. Investors should watch reliable short-interest filings for any true build in shorts.
• Negative Sentiment: Despite the positive fundamental and analyst news, the stock is down today — likely reflection of profit-taking after a recent run toward the 1-year high, or broader market/sector weakness; this intraday decline may be temporary unless follow-through negative news appears.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.